"The Champagne should probably be kept on ice, at least until the two presidents put pen to paper," said state-owned media China Daily.Traderead more
Bloomberg could be in for a showdown with Elizabeth Warren, whether he runs or not.2020 Electionsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Wall Street analysts estimate GM has lost more than $1 billion due to the United Auto Workers' strike, which began Sept. 16.Autosread more
Check out the companies making headlines in midday trading:Market Insiderread more
Harley-Davidson has halted production and deliveries of its new LiveWire electric motorcycle after reportedly discovering a problem with its charging mechanism.Transportationread more
Uber has laid off about 350 employees across several teams within the organization.Technologyread more
A passenger has complained to United Airlines after a fellow traveler was allowed to fly with a T-shirt that called for hanging journalists.Airlinesread more
"I fear that's what we're headed into" here in America, warns the former Treasury secretary.Economyread more
"But I expect we'll have a deal," Mnuchin tells CNBC.Politicsread more
Kohl's stores are getting a bit of a refresh, and are being infused with new brands, ahead of this holiday season.Retailread more
Bank of America Merrill Lynch on Tuesday named Merck its top pick among the many U.S. pharmaceutical stocks thanks to the growing success of its key cancer drug, Keytruda.
"Merck looks well positioned to become the preferred PD1 agent in most major tumor markets, and we estimate upcoming data readouts in lung and renal cancer have the potential to add $4 billion in peak sales or 5 to 10 percent upside," Bank of America's Jason Gerberry wrote in a note to clients.
Investors learned on Friday that Keytruda generated revenues that topped $2 billion in a quarter for the first time, exceeding Wall Street's steep expectations. The better-than-anticipated numbers propelled shares higher, with Merck up nearly 5 percent over the past week.
Keytruda blocks a protein called programmed death receptor 1, or PD-1, on immune cells. It typically works as a type of "off switch" that helps keep the cancer cells from attacking other cells. Sales of the drug soared 66 percent year over year in the fourth quarter and made up nearly 20 percent of the company's total sales of $11 billion worldwide.
"The fourth-quarter and full-year results further bolster our confidence in Merck's innovation-based strategy in which our key pillars — oncology, vaccines, animal health, and select hospital and specialty care products — are expected to drive sustainable growth over the long-term," Merck CEO Kenneth Frazier said in Friday's earnings release. "We enter 2019 with good momentum."
Merck stock rose 1.5 percent in early trading Tuesday after the Bank of America note. The brokerage sees the shares rising to $84 over the next 12 months from Monday's close of $76.87, implying 9 percent upside.
— CNBC's Michael Bloom contributed reporting.